Previous Close | 1.3200 |
Open | 1.3600 |
Bid | 1.3100 x 5100 |
Ask | 1.3400 x 3300 |
Day's Range | 1.3200 - 1.4200 |
52 Week Range | 0.3450 - 2.1050 |
Volume | |
Avg. Volume | 9,742,556 |
Market Cap | 342.246M |
Beta (5Y Monthly) | 3.74 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Ocugen (OCGN) is expected to provide updates regarding the developmental program of its lead candidate, OCU400, for two rare retinal diseases in the first-quarter earnings release.
Ocugen (OCGN) stock gains as the DSMB for the phase I/II study of OCU410 approves the initiation of dosing with the medium dose of OCU410 in the dose-escalation phase of the GA study.